The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products, including dornase alfa, once we have left the EU.
The Department, as part of our EU exit preparations, is implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:
All prescription only medicines and pharmacy medicines imported from or via the EU/European Economic Area are within scope of the continuity of supply programme. All suppliers of these medicines, including suppliers of dornase alfa, have been asked to stockpile medicines and make other preparations as set out in our communications to suppliers.